InfuSystem Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
InfuSystem Holdings, Inc. (INFU) filed this Current Report on Form 8-K on February 5, 2021, to disclose the entry into a new material definitive agreement. The company, incorporated in Delaware, operates through subsidiaries including InfuSystem, Inc., First Biomedical, Inc., and IFC LLC.
Key Financial Metrics and Debt Structure
- New Credit Facility: Entered into a $75 million revolving credit facility maturing on February 5, 2026, with JPMorgan Chase Bank, N.A. as administrative agent.
- Initial Borrowing: Borrowed $30 million on the closing date.
- Letters of Credit: Facility allows for up to $7 million in letters of credit.
- Interest Rates: Variable rates based on LIBO or Alternate Base Rate plus a spread. Initial spreads are 2.00% for Eurodollar loans and 1.00% for ABR loans, varying based on leverage ratios.
- Financial Covenants:
- Minimum Fixed Charge Coverage Ratio: 1.20 to 1.00.
- Maximum Leverage Ratio: 3.50 to 1.00.
- Collateral: Secured by a first priority security interest in substantially all personal property assets of the borrowers.
Material Changes Versus Prior Period
The company terminated its existing 2015 Credit Agreement. Proceeds from the new facility, combined with approximately $8.2 million in cash, were used to repay all amounts due under the 2015 agreement. A letter of credit of approximately $0.8 million was transferred from the old facility to the new one. The company wrote off deferred financing costs of less than $0.1 million associated with the termination of the 2015 agreement.
Outlook, Risks, and Unusual Items
The filing does not provide specific revenue guidance or management commentary on future operational performance. The primary risk disclosed relates to compliance with the new financial covenants; failure to maintain the required ratios could trigger an event of default, allowing lenders to terminate commitments and accelerate payment. The filing notes that the summary is qualified by the full text of the Credit Agreement (Exhibit 10.1).
Key Facts for Investor Verification
- Verify the company's current leverage ratio and fixed charge coverage ratio to ensure compliance with the new 3.50x and 1.20x covenants.
- Confirm the total outstanding debt balance post-refinancing, noting the $30 million initial draw against the $75 million facility.
- Review the full Credit Agreement (Exhibit 10.1) for specific definitions of EBITDA and fixed charges used in covenant calculations.
- Monitor the status of the $0.8 million letter of credit transferred from the prior facility.